Huasun(SZ:000790) Ge Long Hui·2025-12-16 11:09Core Viewpoint - The company aims to enhance asset operation efficiency and focus on core areas by transferring drug marketing licenses and related technologies, as well as signing a project cooperation agreement [1] Group 1: Asset Transfer - The company approved the transfer of production technology and marketing license for smokeless moxibustion sticks to Binjiang Pharmaceutical for a negotiated price of RMB 18 million (including tax) [1] - The transfer is based on the assessed value of the technology and license [1] Group 2: Investment in New Ventures - The company will invest RMB 4.555556 million to acquire a 10% stake in Shanghai Aixingcheng Technology Co., Ltd., which focuses on the operation and management of medicinal moxibustion products [1]